ITRM20000107A0 - Composizione per la prevenzione e/o il trattamento degli effetti citotossici indotti dall'uso di agenti immunosoppressori. - Google Patents

Composizione per la prevenzione e/o il trattamento degli effetti citotossici indotti dall'uso di agenti immunosoppressori.

Info

Publication number
ITRM20000107A0
ITRM20000107A0 IT2000RM000107A ITRM20000107A ITRM20000107A0 IT RM20000107 A0 ITRM20000107 A0 IT RM20000107A0 IT 2000RM000107 A IT2000RM000107 A IT 2000RM000107A IT RM20000107 A ITRM20000107 A IT RM20000107A IT RM20000107 A0 ITRM20000107 A0 IT RM20000107A0
Authority
IT
Italy
Prior art keywords
prevention
treatment
composition
immunosuppressive agents
cytotoxic effects
Prior art date
Application number
IT2000RM000107A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of ITRM20000107A0 publication Critical patent/ITRM20000107A0/it
Priority to IT2000RM000107A priority Critical patent/IT1316998B1/it
Priority to PL358267A priority patent/PL202682B1/pl
Priority to HU0300083A priority patent/HUP0300083A3/hu
Priority to EP01912114A priority patent/EP1267863B1/en
Priority to AU4103101A priority patent/AU4103101A/xx
Priority to SK1189-2002A priority patent/SK11892002A3/sk
Priority to US10/220,185 priority patent/US7897641B2/en
Priority to DK01912114T priority patent/DK1267863T3/da
Priority to AT01912114T priority patent/ATE335476T1/de
Priority to PCT/IT2001/000082 priority patent/WO2001064204A2/en
Priority to CZ20022759A priority patent/CZ20022759A3/cs
Priority to ES01912114T priority patent/ES2269356T3/es
Priority to AU2001241031A priority patent/AU2001241031B8/en
Priority to PT01912114T priority patent/PT1267863E/pt
Priority to CA002400728A priority patent/CA2400728C/en
Priority to DE60122120T priority patent/DE60122120T2/de
Priority to MXPA02008531A priority patent/MXPA02008531A/es
Priority to ARP010100885A priority patent/AR027963A1/es
Priority to TNTNSN01032A priority patent/TNSN01032A1/fr
Publication of ITRM20000107A1 publication Critical patent/ITRM20000107A1/it
Application granted granted Critical
Publication of IT1316998B1 publication Critical patent/IT1316998B1/it
Priority to CY20061101374T priority patent/CY1106169T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2000RM000107A 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. IT1316998B1 (it)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IT2000RM000107A IT1316998B1 (it) 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
CZ20022759A CZ20022759A3 (cs) 2000-03-02 2001-02-20 Přípravek k prevenci a/nebo léčbě cytotoxických účinků vyvolaných používáním imunosupresivních látek
AU2001241031A AU2001241031B8 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
EP01912114A EP1267863B1 (en) 2000-03-02 2001-02-20 Composition consisting of propionyl l-carnitine and glycine for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
AU4103101A AU4103101A (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects inducedby the use of immunosuppressive agents
SK1189-2002A SK11892002A3 (sk) 2000-03-02 2001-02-20 Prostriedok na prevenciu a/alebo liečenie cytotoxických účinkov vyvolaných použitím imunosupresívnych činidiel
US10/220,185 US7897641B2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
DK01912114T DK1267863T3 (da) 2000-03-02 2001-02-20 Sammensætning, der består af propionyl-L-carnitin og glycin, til forebyggelse og/eller behandling af de cytotoksiske effekter, der induceres ved anvendelse af immunosuppressive stoffer
AT01912114T ATE335476T1 (de) 2000-03-02 2001-02-20 Zusammensetzung bestehend aus propionyl l- carnitine und glycine zur verhinderung und/oder behandlung von zytotoxischen effekten infolge der verwendung von immunsuppressiven
PCT/IT2001/000082 WO2001064204A2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
PL358267A PL202682B1 (pl) 2000-03-02 2001-02-20 Kompozycja do zapobiegania i/lub leczenia zmian komórkowych i tkankowych i jej zastosowanie
ES01912114T ES2269356T3 (es) 2000-03-02 2001-02-20 Composicion que consiste en propionil l-carnitina y glicina para la prevencion y/o tratamiento de efectos citotoxicos inducidos por el uso de agentes inmunosupresores.
HU0300083A HUP0300083A3 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
PT01912114T PT1267863E (pt) 2000-03-02 2001-02-20 Composicao constituida por propionil-l-carnitina e glicina para a prevencao e/ou tratamento dos efeitos citotoxicos induzidos pela utilizacao de agentes imunossupressores
CA002400728A CA2400728C (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
DE60122120T DE60122120T2 (de) 2000-03-02 2001-02-20 Zusammensetzung bestehend aus propionyl l-carnitine und glycine zur verhinderung und/oder behandlung von zytotoxischen effekten infolge der verwendung von immunsuppressiven
MXPA02008531A MXPA02008531A (es) 2000-03-02 2001-02-20 Composicion para la prevencion y/o tratamiento de los efectos citotoxicos inducidos por el uso de agentes inmunosupresivos.
ARP010100885A AR027963A1 (es) 2000-03-02 2001-02-27 Composicion para prevencion y/o tratamiento de los efectos citotoxicos inducidos por el uso de agentes inmunosupresores
TNTNSN01032A TNSN01032A1 (fr) 2000-03-02 2001-02-27 Une composition pour la prevention et/ou le traitement des effets cytotoxiques induits par l'utilisation d'agents immunosuppressifs
CY20061101374T CY1106169T1 (el) 2000-03-02 2006-09-25 Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000RM000107A IT1316998B1 (it) 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.

Publications (3)

Publication Number Publication Date
ITRM20000107A0 true ITRM20000107A0 (it) 2000-03-02
ITRM20000107A1 ITRM20000107A1 (it) 2001-09-02
IT1316998B1 IT1316998B1 (it) 2003-05-26

Family

ID=11454493

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2000RM000107A IT1316998B1 (it) 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.

Country Status (19)

Country Link
US (1) US7897641B2 (it)
EP (1) EP1267863B1 (it)
AR (1) AR027963A1 (it)
AT (1) ATE335476T1 (it)
AU (2) AU4103101A (it)
CA (1) CA2400728C (it)
CY (1) CY1106169T1 (it)
CZ (1) CZ20022759A3 (it)
DE (1) DE60122120T2 (it)
DK (1) DK1267863T3 (it)
ES (1) ES2269356T3 (it)
HU (1) HUP0300083A3 (it)
IT (1) IT1316998B1 (it)
MX (1) MXPA02008531A (it)
PL (1) PL202682B1 (it)
PT (1) PT1267863E (it)
SK (1) SK11892002A3 (it)
TN (1) TNSN01032A1 (it)
WO (1) WO2001064204A2 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3135281B8 (en) 2014-04-22 2020-12-23 Ajinomoto Co., Inc. Composition for preventing or improving peripheral neuropathy
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JPH0662547B2 (ja) * 1989-01-10 1994-08-17 田辺製薬株式会社 グリシン誘導体
IT1248323B (it) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti
IT1245869B (it) 1991-06-05 1994-10-25 Sigma Tau Ind Farmaceuti Impiego di propionil l-carnitina per il recupero del tono muscolare in soggetti immobilizzati
US5763408A (en) * 1992-06-03 1998-06-09 Fuji Photo Film Co., Ltd. Amino acid derivatives and application thereof
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
ES2141463T3 (es) * 1996-03-04 2000-03-16 Sigma Tau Ind Farmaceuti Medicamento conteniendo un derivado de la carnitina para el tratamiento de la arteriosclerosis obliterans.
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
IT1302863B1 (it) 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
IT1306173B1 (it) * 1999-07-23 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare.
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
IT1307278B1 (it) * 1999-11-18 2001-10-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
IT1317062B1 (it) * 2000-07-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare utile per prevenire le disfunzioni epatiche ebiliari comprendente una alcanoil l-carnitina.
ITRM20010155A1 (it) * 2001-03-23 2002-09-23 Biosalts Srl Sale di creatina ad aumentato valore nutrizionale e terapeutico e composizioni che lo contengono.

Also Published As

Publication number Publication date
MXPA02008531A (es) 2003-02-12
AU4103101A (en) 2001-09-12
DE60122120D1 (de) 2006-09-21
EP1267863B1 (en) 2006-08-09
PT1267863E (pt) 2006-10-31
DE60122120T2 (de) 2007-02-08
HUP0300083A2 (hu) 2003-06-28
AU2001241031B8 (en) 2005-12-01
ES2269356T3 (es) 2007-04-01
CY1106169T1 (el) 2011-06-08
DK1267863T3 (da) 2006-12-04
AU2001241031B2 (en) 2005-10-27
CA2400728A1 (en) 2001-09-07
SK11892002A3 (sk) 2003-02-04
TNSN01032A1 (fr) 2005-11-10
HUP0300083A3 (en) 2004-07-28
CA2400728C (en) 2009-04-28
WO2001064204A2 (en) 2001-09-07
WO2001064204A3 (en) 2002-03-28
CZ20022759A3 (cs) 2003-02-12
ATE335476T1 (de) 2006-09-15
EP1267863A2 (en) 2003-01-02
US7897641B2 (en) 2011-03-01
US20030144354A1 (en) 2003-07-31
AR027963A1 (es) 2003-04-16
IT1316998B1 (it) 2003-05-26
PL358267A1 (en) 2004-08-09
PL202682B1 (pl) 2009-07-31
ITRM20000107A1 (it) 2001-09-02

Similar Documents

Publication Publication Date Title
MXPA02000282A (es) Composiciones de cuidado personal.
ZA200000603B (en) Use of stilbene derivatives substituted in position 3, as deodrorant active agents in cosmetic compositions.
EE05107B1 (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
CA2429020A1 (en) Use of cci-779 as an antineoplastic agent
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ZA200202802B (en) Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same.
BR0210101A (pt) Combinações antineoplásticas
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
FR2810540B1 (fr) Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
ITRM20000107A0 (it) Composizione per la prevenzione e/o il trattamento degli effetti citotossici indotti dall'uso di agenti immunosoppressori.
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
FR2815856B1 (fr) Utilisation de derives 1,3-diphenylpropane comme actifs inhibant le developpement des odeurs corporelles dans les compositions cosmetiques
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
RU2000118409A (ru) Антимутагенное средство
IT1308057B1 (it) Procedimento e dispositivo per l'impilatura di asciugamani o salvietteinterfogliati
ITRM20000026V0 (it) Struttura integrata per attivita' fisiche e/o estetiche per il corpo.
FR2818131B1 (fr) Composition cosmetique comprenant de l'heparanase
ITMI20001799A0 (it) Accessorio multifunzionale per monitor di "personal-computer" e simili.
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
IT1318540B1 (it) Preparazioni per l'uso intramuscolare di bisfosfonati.
ITRM20000624A0 (it) Uso di derivati dell'acidocinnamico come agenti insetticidi.
IT1310374B1 (it) Teca per l'esposizione in sicurezza di oggetti.
IT1312375B1 (it) Composizione topica per l'eliminazione di tatuaggi.